(Total Views: 569)
Posted On: 09/21/2020 1:46:14 PM
Post# of 153832
I think there is a reasonable chance that our CD12 efficacy earns an EUA, but we will have to see.
If it does not, we will launch the new Moderate trial and refocus on enrollment in the severe. Depending on the spread of COVID, I would think we could complete enrollment in both by the end of the year, but we would need to increase the pace of enrollment in severe.
Im sure the pace of enrollment can be debated six ways from Sunday, but I would think we can all agree that the more information that is published about Leronlimab, the easier it will be to obtain enrollment. While, the opposite is true if other drugs show efficacy and are approved (will make enrollment more difficult).
However, realistically if another drug becomes the SOC in the next couple of months, it will take time to scale and distribute, so I dont foresee other drugs impeding our enrollment for a while.
If it does not, we will launch the new Moderate trial and refocus on enrollment in the severe. Depending on the spread of COVID, I would think we could complete enrollment in both by the end of the year, but we would need to increase the pace of enrollment in severe.
Im sure the pace of enrollment can be debated six ways from Sunday, but I would think we can all agree that the more information that is published about Leronlimab, the easier it will be to obtain enrollment. While, the opposite is true if other drugs show efficacy and are approved (will make enrollment more difficult).
However, realistically if another drug becomes the SOC in the next couple of months, it will take time to scale and distribute, so I dont foresee other drugs impeding our enrollment for a while.
(2)
(0)
